An Identification System for Targeted Gene Addition to MLD Patient Derived iPSCs
用于向 MLD 患者衍生的 iPSC 添加靶向基因的鉴定系统
基本信息
- 批准号:8822754
- 负责人:
- 金额:$ 17.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-30 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibioticsArylsulfatasesAutomobile DrivingBindingBiological AssayBrain DiseasesCCR5 geneCMV promoterCandidate Disease GeneCellsCessation of lifeChimeric ProteinsClonal ExpansionClustered Regularly Interspaced Short Palindromic RepeatsDNADNA Binding DomainDetectionDiseaseEventFlareFluorescence-Activated Cell SortingGene ExpressionGene TargetingGenesGenomeGenomicsGoalsHumanHuman Cell LineInsertional MutagenesisLeadMessenger RNAMetachromatic LeukodystrophyMethodsModificationMutationNeomycinNerve DegenerationNeuraxisNeurodegenerative DisordersOutcomeParentsPaste substancePatientsPopulationPopulation HeterogeneityProductionReplacement TherapyReporterRiskSafetySiteSystemTherapeuticTranscription CoactivatorTransgenesTransposasebaseexomeexome sequencinggene correctiongene therapygenotoxicityhomologous recombinationimprovedinduced pluripotent stem cellinfancynanonerve stem cellnucleasepublic health relevancetransgene expression
项目摘要
DESCRIPTION: Patient-specific induced pluripotent stem cells (iPSCs) hold enormous promise for personalized cell replacement therapy. Metachromatic leukodystrophy (MLD) is a neurodegenerative disease that, like many other monogenetic disorders, is a candidate for gene therapy using corrected iPSCs. Realizing the full potential of iPSCs requires reliable methods for performing gene targeting. A major challenge is reducing the risk of insertional mutagenesis due to random insertion. Targetable nucleases based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas9) and transcription activator like effector (TALE) nuclease (TALEN) systems are capable of inducing double stranded breaks (DSBs). These DSBs can enhance homologous recombination for the introduction of transgenes at specific sequences. However, off-target DNA cleavages at unknown sites can lead to mutations that are difficult to detect. Alternatively, a targetable piggyBac (pB) transposase has recently been used by us to direct integration into a single genomic address. Currently, no direct comparison of genotoxicity between any pair of these strategies has been conducted. Importantly, all current methods significantly integrate at off-target sites necessitating a reliable system for the identification of safely modified cells. Our goal is to improve both the safety and efficiency in correcting a human iPSC gene deficiency using a combination of directed gene addition and target event detection. We have devised a tunable enrichment strategy, termed event detection, that will allow for the identification and isolation o rare correctly modified cells following targeted gene addition. We will use CRISPR, TALEN, and our recently developed targetable transposase system to target our event detection cassette to the ROSA26 genomic safe harbor. After validating multiple strategies in a human cell line we will apply event detection for use in identifying gene corrected iPSCs originally derived from an MLD patient. Furthermore, we will verify MLD transgene expression from neural precursors derived from safely modified iPSCs. Finally, exome sequencing will be performed before and after iPSC manipulation to identify mutations arising from different gene addition strategies.
患者特异性诱导多能干细胞(iPSC)为个性化细胞替代疗法带来了巨大的希望。异染性脑白质营养不良(MLD)是一种神经退行性疾病,与许多其他单基因疾病一样,是使用纠正的iPSC进行基因治疗的候选者。实现iPSC的全部潜力需要可靠的基因靶向方法。一个主要的挑战是减少由于随机插入而引起的插入诱变的风险。基于成簇的规律间隔的短回文重复序列(CRISPR)/CRISPR相关的(Cas9)和转录激活因子样效应物(TALE)核酸酶(TALEN)系统的靶向核酸酶能够诱导双链断裂(DSB)。这些DSB可以增强同源重组以在特定序列处引入转基因。然而,在未知位点的脱靶DNA切割可能导致难以检测的突变。或者,我们最近使用可靶向的piggyBac(pB)转座酶来直接整合到单个基因组地址中。目前,尚未对任何一对这些策略之间的遗传毒性进行直接比较。重要的是,所有目前的方法在脱靶位点显著整合,需要可靠的系统来鉴定安全修饰的细胞。我们的目标是使用定向基因添加和靶事件检测的组合来提高纠正人iPSC基因缺陷的安全性和效率。我们已经设计了一种可调的富集策略,称为事件检测,这将允许在靶向基因添加后鉴定和分离罕见的正确修饰的细胞。我们将使用CRISPR,TALEN和我们最近开发的可靶向转座酶系统将我们的事件检测盒靶向ROSA 26基因组安全港。在人细胞系中验证多种策略后,我们将应用事件检测用于鉴定最初来源于MLD患者的基因校正的iPSC。此外,我们将验证来自安全修饰的iPSC的神经前体的MLD转基因表达。最后,将在iPSC操作之前和之后进行外显子组测序,以鉴定由不同基因添加策略引起的突变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEFAN MOISYADI其他文献
STEFAN MOISYADI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEFAN MOISYADI', 18)}}的其他基金
Transposon Based Mammalian Transgenesis and Transfection
基于转座子的哺乳动物转基因和转染
- 批准号:
7645055 - 财政年份:2008
- 资助金额:
$ 17.64万 - 项目类别:
Transposon Based Mammalian Transgenesis and Transfection
基于转座子的哺乳动物转基因和转染
- 批准号:
8266439 - 财政年份:2008
- 资助金额:
$ 17.64万 - 项目类别:
Transposon Based Mammalian Transgenesis and Transfection
基于转座子的哺乳动物转基因和转染
- 批准号:
7848092 - 财政年份:2008
- 资助金额:
$ 17.64万 - 项目类别:
Transposon Based Mammalian Transgenesis and Transfection
基于转座子的哺乳动物转基因和转染
- 批准号:
8069618 - 财政年份:2008
- 资助金额:
$ 17.64万 - 项目类别:
Transposon Based Mammalian Transgenesis and Transfection
基于转座子的哺乳动物转基因和转染
- 批准号:
7526462 - 财政年份:2008
- 资助金额:
$ 17.64万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 17.64万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 17.64万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 17.64万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 17.64万 - 项目类别:
Studentship